Intra-Cellular Therapies
ITCI
#1494
Rank
NZ$24.29 B
Marketcap
NZ$228.11
Share price
0.00%
Change (1 day)
93.13%
Change (1 year)

Revenue for Intra-Cellular Therapies (ITCI)

Revenue in 2024 (TTM): NZ$1.13 Billion

According to Intra-Cellular Therapies's latest financial reports the company's current revenue (TTM ) is NZ$1.17 Billion. an increase over the revenue in the year 2023 that were of NZ$0.73 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Intra-Cellular Therapies from 2014 to 2024

Annual revenue

Year Revenue Change
2024 NZ$1.20 B65.1%
2023 NZ$0.73 B86.25%
2022 NZ$0.39 B228.02%
2021 NZ$0.11 B283.09%
2020 NZ$31.22 M34595.48%
2019 NZ$0.09 M
2018 N/A
2017 N/A
2016 N/A-100%
2015 NZ$0.04 M-93.59%
2014 NZ$0.69 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
MediciNova
MNOV
NZ$0.44 M-99.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Curis
CRIS
NZ$20.15 M-98.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Xencor
XNCR
NZ$0.28 B-75.41%๐Ÿ‡บ๐Ÿ‡ธ USA